Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro

European Journal of Haematology

Volumn 68, Issue 6, 2002, Pages 370-375

  Szmigielska Kaplon, Anna ^a   Ciesielska, Ewa ^a   Szmigiero, Leszek ^a   Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cladribine; Doxorubicin; Idarubicin; Interactions; Leukemia; Mitoxantrone

Indexed keywords

ANTHRACYCLINE; CLADRIBINE; DOXORUBICIN; IDARUBICIN; MITOXANTRONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOSTASIS; DNA DAMAGE; DNA REPAIR; DRUG POTENTIATION; LEUKEMIA; MALE; MOUSE; MURINE LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL SURVIVAL; CLADRIBINE; DOXORUBICIN; IDARUBICIN; LEUKEMIA L1210; LEUKEMIA P388; MICE; MITOXANTRONE; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0036621027     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2002.01598.x     Document Type: Article

References (37)

1. TALLMAN MS, HAKIMIAN D. Purine nucleoside analogs: emerging roles in indolent lymohoproliferative disorders. Blood 1995;86:246-2472.
2. ROBAK T. Cladribine in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 2001;40:551-564.
3. PIRO LD, CARRERA CJ, CARSON DA, BEUTLER E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990;322:1117-1121.
4. ROBAK T, BLOÑKI JZ, KASZNICKI M, et al. Cladribine with prednisone vs. chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia. Report of a prospective, randomized, multicenter trial. Blood 2000;96:2723-2729.
5. HOFFMAN M, TALLMAN MS, HAKIMIAN D, et al. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol 1994;12:788-772.
6. ROBAK T, WRZESIEÑ-KUS A, LECH-MARAÑDA E, KOWAL M, DMOSZYÑSKA A. Combination regimen of cladribine, cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 2000;39:121-129.
7. VAN DEN NESTE E, BONTEMPS F, DELACAUW A, et al. Potentiation of antitumor effects of cyclophosphamide derivates in B-chronic lymphocytic leukemia cells by 2-chlorodeoxyadenosine. Leukemia 1999;13:918-925.
8. GORA-TYBOR J, ROBAK T. Synergistic action of 2-chlorodeoxyadenosine cyclophosphamide on murine leukemia L1210. Acta Haematol Pol 1993;24:177-182.
9. HOFFMAN M, XU JC, LESSER M, RAI K. Cytotoxicity of 2-chlorodeoxyadenosine (cladribine, 2-CdA) in combination with other chemotherapy drugs against two lymphoma cell lines. Leuk Lymphoma 1999;33:141-145.
10. VAN DEN NESTE E, LOUVIAUX I, MICHAUX JL, et al. Phase I/II of 2-chlorodeoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Leukemia 2000; 14:1136-1142.
11. LAURENCET FM, ZULIAN GB, GUETTY-ALBERTO M, ITEN PA, BETTICHER DC, ALBERTO P, Cladribine with cyclophocphamide and prednisone in the management of low-grade lymphoproliferative malignancies. Br J Cancer 1999;79:1215-1219.
12. KANO Y, AKUTSU M, TSUNODA S, et al. In vitro cytotoxicty effects of fludarabine (2-Fara-A) in combination with commonly used antileukemic agents by isobologram analysis. Leukemia 2000;14:379-388.
13. ROBERTSON LE, O'BRIEN S, KANTARJIAN H, et al. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia 1995;9:943-945.
14. MCLAUGHLIN P, HAGEMAISTER FB, ROMAGUERA JE, et al. Fludarabine, mitoxantrone and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 1996; 14:1262-1268.
15. SAVEN A, LEE T, KOSTY M, PIRO L. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma. J Clin Oncol 1996;14:1262-1268.
16. ROBAK T, GORA-TYBOR J, LECH-MARAÑDA E, BLOÑSKI JZ, KASZNICKI M. Cladribine in combination with mitoxantrone and cyclophosphamide (CMD) in the treatment of heavily pretreated patients with advanced indolent lymphoid malignancies. Eur J Haematol 2001;66:188-194.
17. O'BRIEN SM, KANTARJIAN HM, CORTES J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001; 19:1414-1420.
18. ROBAK T, BLOÑSKI JZ, KASZNICKI M et al. Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. Leukemia 2001;15:in press.
19. WEISS RB. The anthracyclines: will we find a better doxorubicin? Semin Oncol 1992;19:670-686.
20. ZINZANI PL, TURA S, CAJOZZO A, et al. Anthracycline containing regimens in intermediate grade lymphoma. Leuk Lymphoma 1993;10:39-41.
21. HOLLINGSHEAD LM, FAULDS D. Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the chemotherapy of cancer. Drugs 1991;42:690-719.
22. FAULDS D, BALFOUR JA, CHRISP P, LANGTRY HD. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the chemotherapy of cancer. Drugs 1991;41:400-449.
23. BELLOSILLO B, VILLAMO N, COLOMER D, PONS G, MONSERRAT E, Gil J. In vitro evaluation of fludarabine in combination with cyclophocphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 1999;95:2836-2843.
24. CHOW KU, RUMMEL MJ, WEICHMANN E, et al. Induction of apoptosis by 2-chloro-2-deoxyadenosine (2-CdA) alone and in combination with other cytostatic drugs: synergistic effect on normal and neoplastic lymphocytes by addition of doxorubicin and mitoxantrone. Leuk Lymphoma 2000; 36:559-567.
25. KAZIMIERCZUK Z, COTTAM HB, REVANKER GR, ROBINS RK. Synthesis of 2-deoxynucleotides via a novel direct stereospecific sodium salt glycosylation procedure. JACS 1984; 106:6379-6382.
26. MARAÑDA E, SZMIGIELSKA A, ROBAK T. Additive action of gemcitabine (2′2′-difluorodeoxycytidine) and 2-chlorodeoxyadenosine on murine leukemias L1210 and P388. Cancer Invest 1999;17:95-101.
27. POTEMSKI P, POLAKOWSKI P. Metoclopramide and Nitrendipine are unable to enhance cytotoxicity of mitoxantrone in sensitive and resistant murine leukemias in vivo. Arch Immunol Ther Exp 1997;45:249-253.
28. ZAGOZDZON R, GOLAB J, STOKLOSA T, et al. Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin. Int J Cancer 1998;77:720-727.
29. GERAN RJ, GREENBERG NH, MACDONALD MM. Protocols for screening chemical agents and natural products against animal tumors and others biological systems. Cancer Chemother Rep 1972;3:1.
30. MORABITO F, CALLEA I, CONSOLE G. The in vitro cytotoxic effect of mitoxantrone in combination with fludarabine in B-cell chronic lymphocytic leukemia. Hematologica 1997; 82:560-565.
31. PASTWA E, CIESIELSKA E, PIESTRZENIEWICZ MK, DENNY WA, GNIAZDOWSKI M, SZMIGIERO L. Cytotoxic and DNA-damaging properties of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide (DACA) and its analogues. Biochem Pharmacol 1998;56:351-359.
32. FRITZER-SZEKERES M, NOVOTNY L, ROMANOVA D, et al. Enhanced effects of adriamycin by combination with a new ribonucleotide reductase inhibitor, trimidox, in murine leukemia. Life Sci 1998;63:545-552.
33. MATTERN J, VOLM M. Clinical relevance of predictive tests for cancer chemotherapy. Cancer Treat Rev 1982;9:267-269.
34. RISCOE MK, BROUNS MC, FITCHEN JH. Purine metabolism as a target for leukemia chemotherapy. Blood Rev 1989;3:162-173.
35. LIU LF. DNA topoisomerase poisons as antitumor drugs. Ann Rev Biochem 1989;58:351-375.
36. GANDHI V, HUANG P, PLUNKETT W. Fludarabine inhibits DNA replication. A rationale for its use in the treatment of acute leukemias. Leuk Lymphoma 1994;14:3-9.
37. CUMMINGS J, ANDERSON L, WILLMOTT N, SMYTH JF. The molecular pharmacology of doxorubicin in vivo. Eur J Cancer 1991;27:532-535.